Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer

2019 ◽  
Author(s):  
Keyword(s):  
Breast Cancer ◽  
Aromatase Inhibitor ◽  
Postmenopausal Breast Cancer

Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer

2021 ◽  
Vol 385 (5) ◽  
pp. 395-405 ◽  
Author(s):  
Michael Gnant ◽  
Florian Fitzal ◽  
Gabriel Rinnerthaler ◽  
Guenther G. Steger ◽  
Sigrun Greil-Ressler ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Aromatase Inhibitor ◽  
Postmenopausal Breast Cancer ◽  
Inhibitor Therapy ◽  
Aromatase Inhibitor Therapy

scholarly journals Effects of Vaginal Estrogens on Serum Estradiol Levels in Postmenopausal Breast Cancer Survivors and Women at Risk of Breast Cancer Taking an Aromatase Inhibitor or a Selective Estrogen Receptor Modulator

2012 ◽  
Vol 8 (3) ◽  
pp. 144-148 ◽  
Author(s):  
Shannon Wills ◽  
Anita Ravipati ◽  
Padmaja Venuturumilli ◽  
Cynthia Kresge ◽  
Elizabeth Folkerd ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Cancer Survivors ◽  
Aromatase Inhibitor ◽  
Breast Cancer Survivors ◽  
Postmenopausal Breast Cancer ◽  
Serum Estradiol ◽  
Estradiol Treatment ◽  
Receptor Modulator ◽  
Estradiol Levels

The authors conclude that intravaginal estradiol treatment, regardless of type, results in elevated circulating E2 levels in this population and should be used with caution.

Pharmacokinetics and pharmacodynamics of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione in patients with postmenopausal breast cancer

1991 ◽  
Vol 27 (5) ◽  
pp. 367-372 ◽  
Author(s):  
Benjamin P. Haynes ◽  
Michael Jarman ◽  
Mitchell Dowsett ◽  
Anshumala Mehta ◽  
Per E. L�nning ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Aromatase Inhibitor ◽  
Postmenopausal Breast Cancer ◽  
Pharmacokinetics And Pharmacodynamics
Sign in / Sign up

Export Citation Format

Share Document